Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
Hironaga SatakeAkihito TsujiMasato NakamuraMasaaki OgawaTakeshi KotakeYukimasa HatachiHisateru YasuiAkinori TakaganeYoshihiro OkitaKumi NakamuraToshihide OnikuboMasahiro TakeuchiMasashi FujiiPublished in: International journal of clinical oncology (2018)
The FOLFOXIRI + panitumumab chemotherapy regimen was well tolerated by our patients with mCRC and showed promising anti-tumor activity. The recommended phase II dose was determined to be the same as the standard doses of this regimen used worldwide.